Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Corporate volunteering boosts social impact - A win for all.
Boehringer Ingelheim corporate volunteers help people with disabilities. Volunteering has social impact and benefits employees, employers, and communities.
Collaboration with external partners is a fundamental part of our innovation strategy in Animal Health. Learn more about the partners we are looking for.
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.